1-(naphthalen-2-ylmethyl)piperidin-4-one | 474843-76-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(naphthalen-2-ylmethyl)piperidin-4-one
• CAS: 474843-76-0
• 化学式: C₁₆H₁₇NO
• 分子量: 239.317
• InChiKey: NLLCMHIEDAAFLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(naphthalen-2-ylmethyl)piperidin-4-one 在 吗啉 、 sulfur 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 94.0h， 生成 6-Naphthalen-2-ylmethyl-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid
  参考文献：
  名称：

  Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

  摘要：

  Reversible phosphorylation and dephosphorylation of key proteins on tyrosine residues are important parts of intracellular signaling triggered by hormones and other agents. Recent knock-out studies in mice have identified PTP1B as a potential target for the treatment of diabetes and obesity. As a consequence, a number of academic and industrial groups are aggressively pursuing the development of selective PTP1B inhibitors. In addition, other protein-tyrosine phosphatases (PTPs) appear to be critically involved in major diseases such as cancer and autoimmunity. Given the diversity of PTPs and their potential as drug targets in different diseases, we have taken a broad approach to develop active site-directed selective inhibitors of specific members of this family of enzymes. Using a high throughput screening, we have previously identified 2-(oxalylamino)benzoic acid 3a as a relatively weak but classical competitive inhibitor of several PTPs.(4) On the basis of our early studies, indicating that 3a might be used as a starting point for the synthesis of selective PTP inhibitors, we now present our efforts in expansion of this concept and provide here a number of new chemical scaffolds for the development of inhibitors of different members of the PTP family. Although the core structure of these inhibitors is charged, good oral bioavailability has been observed in rat for some compounds. Furthermore, we have observed enhancement of 2-deoxy-glucose accumulation in C2C12 cells with prodrug analogues.

  DOI：

  10.1021/jm0209026
• 作为产物：
  描述：

  4-哌啶酮缩乙二醇 在 盐酸 、 potassium carbonate 、 溶剂黄146 、 potassium iodide 作用下， 以 various solvent(s) 为溶剂， 反应 23.0h， 生成 1-(naphthalen-2-ylmethyl)piperidin-4-one
  参考文献：
  名称：

  Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

  摘要：

  Reversible phosphorylation and dephosphorylation of key proteins on tyrosine residues are important parts of intracellular signaling triggered by hormones and other agents. Recent knock-out studies in mice have identified PTP1B as a potential target for the treatment of diabetes and obesity. As a consequence, a number of academic and industrial groups are aggressively pursuing the development of selective PTP1B inhibitors. In addition, other protein-tyrosine phosphatases (PTPs) appear to be critically involved in major diseases such as cancer and autoimmunity. Given the diversity of PTPs and their potential as drug targets in different diseases, we have taken a broad approach to develop active site-directed selective inhibitors of specific members of this family of enzymes. Using a high throughput screening, we have previously identified 2-(oxalylamino)benzoic acid 3a as a relatively weak but classical competitive inhibitor of several PTPs.(4) On the basis of our early studies, indicating that 3a might be used as a starting point for the synthesis of selective PTP inhibitors, we now present our efforts in expansion of this concept and provide here a number of new chemical scaffolds for the development of inhibitors of different members of the PTP family. Although the core structure of these inhibitors is charged, good oral bioavailability has been observed in rat for some compounds. Furthermore, we have observed enhancement of 2-deoxy-glucose accumulation in C2C12 cells with prodrug analogues.

  DOI：

  10.1021/jm0209026

文献信息

• Structure‐Based Design and Synthesis of Piperidinol‐Containing Molecules as New <i>Mycobacterium abscessus</i> Inhibitors
  作者：Jérôme Ruyck、Christian Dupont、Elodie Lamy、Vincent Le Moigne、Christophe Biot、Yann Guérardel、Jean‐Louis Herrmann、Mickaël Blaise、Stanislas Grassin‐Delyle、Laurent Kremer、Faustine Dubar

  DOI：10.1002/open.202000042

  日期：2020.3

  using standard chemotherapy. We previously demonstrated that a piperidinol derivative, named PIPD1, is an efficient molecule both against M. abscessus and Mycobacterium tuberculosis, the agent of tuberculosis, by targeting the mycolic acid transporter MmpL3. These results prompted us to design and synthesize a series of piperidinol derivatives and to determine the biological activity against M. abscessus

  非结核分枝杆菌 (NTM) 感染，例如由脓肿分枝杆菌引起的感染，在全球范围内正在增加。由于其固有的耐药性，脓肿分枝杆菌肺部感染通常难以使​​用标准化疗来治愈。我们之前证明，一种名为 PIPD1 的哌啶醇衍生物是一种有效的分子，通过靶向分枝菌酸转运蛋白 MmpL3，对抗脓肿分枝杆菌和结核病病原体结核分枝杆菌。这些结果促使我们设计并合成了一系列哌啶醇衍生物，并确定其对抗脓肿分枝杆菌的生物活性。构效关系（SAR）研究指出了支架上可以承受轻微修改的特定位点。总体而言，这些结果表明 FMD-88 是一种新的有前途的抗脓肿分枝杆菌活性类似物。此外，我们还确定了 PIPD1 的药代动力学特性，并表明腹膜内给药该化合物可产生令人鼓舞的血清浓度和 3.2 小时的消除半衰期。
• Identification of novel benzoyl hydrazine derivatives as activators of neddylation pathway to inhibit the tumor progression in vitro
  作者：Xuan Wang、Sumeng Guan、Zunming Tian、Mei Zhao、Mengyu Li、Hua Yang、Ling Zhu、Moran Sun

  DOI：10.1007/s00044-024-03193-4

  日期：2024.3

  against A549, MGC-803, MCF-7KYSE-30 cell lines. The cell-based mechanistic studies showed that IIb-10 bearing the benzoyl hydrazine motif can selectively inhibit the Neddylation modification of Cullin1 and Cullin3 by inhibiting NEDD8 activase and then, leads to a dose-dependent reduction in the level of UBC12-NEDD8 complex via interacting with NAE1 directly. Cellular mechanisms elucidated that compound

  Neddylation 修饰在许多类型的人类肿瘤中经常过度表达。因此，靶向neddylation途径已被确定为可行的抗癌治疗策略。 NEDD8 激活酶 (NAE) 在多种细胞功能中发挥着至关重要的作用。在这里，开发、生产了一个新的哌啶类似物文库，并评估了其对 A549、MGC-803、MCF-7KYSE-30 细胞系的抗增殖功效。基于细胞的机制研究表明，带有苯甲酰肼基序的IIb-10可以通过抑制 NEDD8 激活酶来选择性抑制 Cullin1 和 Cullin3 的 Neddylation 修饰，然后通过相互作用导致 UBC12-NEDD8 复合物水平呈剂量依赖性降低。直接与NAE1。细胞机制阐明化合物IIb-10能够使 MGC-803 细胞的细胞周期停止在 G2/M 期并引发细胞凋亡。总而言之，酰肼连接的哌啶衍生物可能是作为开发高效neddylation抑制剂的先导化合物的有前途的候选者。
• Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors
  作者：V. Blair Journigan、Christophe Mésangeau、Neha Vyas、Shainnel O. Eans、Stephen J. Cutler、Jay P. McLaughlin、Catherine Mollereau、Christopher R. McCurdy

  DOI：10.1021/jm500989n

  日期：2014.11.13

  Neuropeptide FF1 and FF2 receptors (NPFF1-R and NPFF2-R), and their endogenous ligand NPFF, are one of only several systems responsible for mediating opioid-induced hyperalgesia, tolerance, and dependence. Currently, no small molecules displaying good affinity or selectivity for either subtype have been reported, to decipher the role of NPFF2-R as it relates to opioid-mediated analgesia, for further exploration of NPFF1-R, or for medication development for either subtype. We report the first nonpeptide small molecule scaffold for NPFF1,2-R, the guanidino-piperidines, and SAR studies resulting in the discovery of a NPFF1 agonist (7b, K-i = 487 +/- 117 nM), a NPFF1 antagonist (46, K-i = 81 +/- 17 nM), and a NPFF2 partial antagonist (53a, K-i = 30 +/- 5 nM), which serve as leads for the development of pharmacological probes and potential therapeutic agents. Testing of 46 alone was without effect in the mouse 48 degrees C warm-water tail-withdrawal test, but pretreatment with 46 prevented NPFF-induced hyperalgesia.
• FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC
  申请人：Burns Barbier Lindsay

  公开号：US20110105484A1

  公开（公告）日：2011-05-05

  A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within.
• US8580808B2
  申请人：——

  公开号：US8580808B2

  公开（公告）日：2013-11-12